Shaji Theodore

***** ***** **** ** #***, Richmond, Virginia 23233; Email: ab02jm@r.postjobfree.com

SUMMARY OF SKILLS

• Substantial knowledge of pharmacology, toxicology and pathology with exceptional ability to relate

biochemical changes at molecular level to the organism level

• Extensive knowledge of principles of toxicology and experience with survival surgery in animal

models

• Familiarity with GLP studies in drug discovery research

• Experienced in handling and dosing of rodents and non-rodents and pre-clinical toxicity studies

• Strong written and verbal communication skills

CITIZENSHIP

Permanent Resident of USA

EDUCATION

May 2006, PhD (Toxicology), University of Kentucky at Lexington, USA

GPA 4.0/4.0

Oct 1997, MVSc (Pharmacology), Tamilnadu Veterinary and Animal Sciences University, India

GPA 9.6/10.0

May 1995, BVSc (Veterinary Medicine), Tamilnadu Veterinary and Animal Sciences University, India

GPA 3.18/4.0

EMPLOYMENT

Research Scientist in Neurology

Mar 2010-present

Virginia Commonwealth University, Richmond, Virginia

• Three years of independently managing neurotoxicity research project

• Set up and organize a fully functional laboratory

• Write and submit research grant

Postdoctoral Fellow in Neurology

Sep 2006-Oct2009

The University of Alabama at Birmingham, Alabama

• Designed and executed neurotoxicity studies in a mouse model

• Successfully obtained research grants

• Communicated original research findings at meetings and in scientific journals

Scientist, Pre-clinical Safety Evaluation

Jun 1998-Jul1999

Torrent Pharmaceuticals, India

• Designed and carried out repeated dose toxicity studies in rodents

• Assisted the study director with compiling and submitting toxicology reports

• Assisted with creating SOPs and implementing GLP in the toxicology lab

TECHNICAL SKILLS

• parenteral and oral drug administration in rodents and pre-clinical safety evaluation tests in rodents

and non-rodents for various new chemical entities

• Post-mortem examination of rodents and non-rodents

• rodent stereotaxic surgical techniques

• confocal microscopy and stereological analysis

• cell biology techniques such as immunoblotting, immunoflourescence, advanced microscopy,

transfection, quantitative PCR, cell culture techniques and ELISA

• viral vector packaging and purification and targeted in vivo delivery

SCHOLASTIC HONORS

• Gold Medal in Pharmacology and Toxicology 1996

Madras Veterinary College, Chennai, India

• Commonwealth Opportunity Fellowship 2003

University of Kentucky, Lexington, USA

RESEARCH AWARDS WON

American Parkinson’s Disease Association Postdoctoral Fellowship

Jul 07 - Jul08

Project: A Novel Mode of Microglial Activation in a Mouse Model of Parkinson’s Disease.

Parkinson’s Disease Foundation Research Grant

Jul 08 – Jul 09

Project: Pharmacological Inhibition of Nuclear Factor – Kappa B in a Mouse Model of Parkinson’s

Disease.

American Parkinson’s Disease Association Research Grant

Jul 08 – Jul 09

Project: Inhibiting Nuclear Factor – Kappa B signaling and Microglial Activation in a Mouse Model of

Parkinson’s Disease.

PROFESSIONAL PUBLICATIONS

1. Theodore S, Cass W, Dwoskin L and Maragos WF. HIV-1 Protein Tat Inhibits Vesicular Monoamine

Transporter-2 Activity in Rat Striatum. Synapse, 66(8):755-7, 2012.

2. Cao S, Theodore S and Standaert DG. Lack of Fcγ Receptors Inhibits NF-κB activation, Reduces

Microglial Activation and Prevents Dopaminergic Neurodegeneration in a Mouse Model of Parkinson’s

Disease. Molecular Neurodegeneration, 5:42, 2010.

3. Theodore S, Cao S, McLean PJ, and Standaert DG. Targeted Over-expression of Human Alpha-

Synuclein triggers both Microglial Activation and an Adaptive Immune Response in a Mouse Model of

Parkinson Disease. J. Neuropath. Exp Neurol, 67(12): 1149-1158, 2008.

4. Theodore S*, Cass WA, Nath A and Maragos WF. Progress in Understanding Basal Ganglia Dysfunction

as a Common Target for Methamphetamine Abuse and HIV-1 Neurodegeneration. Current HIV Research, 5

(3): 301-313, 2007.

5. Theodore S, Cass WA, Nath A, Steiner J, Young KL and Maragos WF. Inhibition of Tumor Necrosis

Factor-α Signaling prevents Human Immunodeficiency Virus-1 Protein Tat and Methamphetamine

Interaction. Neurobiology of Disease, 23(3): 663-668, 2006.

6. Theodore S, Stolberg S, Cass WA and Maragos WF. Human Immunodeficiency Virus-1 Protein Tat and

Methamphetamine Interactions. Ann. NY. Acad. Sci, 1074: 178-190, 2006.

7. Theodore S, Cass WA and Maragos WF. Involvement of Cytokines in Human Immunodeficiency Virus-1

Protein Tat and Methamphetamine Interactions in the Striatum. Experimental Neurology. 199: 490-498,

2006.

8. Theodore S, Cass WA and Maragos WF. Methamphetamine and Human Immunodeficiency Virus

Protein Tat Synergize to Destroy Dopaminergic Terminals in the Rat Striatum. Neuroscience. 137 (3): 925-

935, 2006.

9. Orren DK, Theodore S, Machwe A. The Werner Syndrome Helicase/Exonuclease (WRN) Disrupts and

Degrades D-Loops in Vitro. Biochemistry. 41(46): 13483-8, 2002.

10. Machwe A, Xiao L, Theodore S and Orren DK. DNase I foot-printing and enhanced exonuclease

function of the bipartite Werner syndrome protein (WRN) bound to partially melted duplex DNA. Journal of

Biological Chemistry. 277(6): 4492-504, 2002.

* Corresponding author

Contact this candidate